Pfizer Inc. $PFE Shares Sold by Virtue Capital Management LLC

Virtue Capital Management LLC decreased its position in shares of Pfizer Inc. (NYSE:PFE) by 48.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 12,910 shares of the biopharmaceutical company’s stock after selling 12,022 shares during the quarter. Virtue Capital Management LLC’s holdings in Pfizer were worth $313,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. Brighton Jones LLC boosted its position in shares of Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock worth $17,677,000 after buying an additional 618,117 shares during the period. Revolve Wealth Partners LLC boosted its position in Pfizer by 12.5% during the 4th quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after acquiring an additional 2,087 shares during the period. Harvest Fund Management Co. Ltd grew its stake in shares of Pfizer by 12,069.0% in the first quarter. Harvest Fund Management Co. Ltd now owns 7,058 shares of the biopharmaceutical company’s stock worth $179,000 after purchasing an additional 7,000 shares in the last quarter. Vestcor Inc grew its stake in shares of Pfizer by 4.6% in the first quarter. Vestcor Inc now owns 108,719 shares of the biopharmaceutical company’s stock worth $2,755,000 after purchasing an additional 4,746 shares in the last quarter. Finally, Bayforest Capital Ltd bought a new stake in shares of Pfizer during the first quarter valued at about $28,000. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer Stock Up 0.2%

PFE stock opened at $25.76 on Friday. The firm has a market cap of $146.46 billion, a PE ratio of 13.70, a P/E/G ratio of 0.81 and a beta of 0.54. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.69. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.16 and a quick ratio of 0.85. The firm has a 50 day simple moving average of $25.01 and a 200 day simple moving average of $24.57.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.08. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The company had revenue of $16.65 billion for the quarter, compared to analysts’ expectations of $16.94 billion. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. Equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Investors of record on Friday, November 7th will be given a $0.43 dividend. The ex-dividend date is Friday, November 7th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. Pfizer’s dividend payout ratio (DPR) is 100.00%.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on PFE. Citigroup increased their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a “neutral” rating in a research report on Wednesday, August 6th. Morgan Stanley decreased their price objective on shares of Pfizer from $33.00 to $32.00 and set an “equal weight” rating for the company in a report on Friday, October 10th. UBS Group reiterated a “neutral” rating and set a $28.00 price objective on shares of Pfizer in a research note on Wednesday, October 1st. Sanford C. Bernstein restated a “market perform” rating and issued a $30.00 target price on shares of Pfizer in a research report on Friday, October 31st. Finally, Scotiabank began coverage on Pfizer in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $30.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $28.39.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.